| Literature DB >> 32507806 |
Akira Matsumoto1, Yoshiyuki Ogawa1,2, Tsukasa Osaki2,3, Masayoshi Souri2,3, Kunio Yanagisawa1, Takuma Ishizaki1, Chiaki Naito1, Tetsuya Ishikawa1, Yuri Miyazawa1, Hiroaki Shimizu1, Madoka Inoue4, Masaki Hayakawa4, Masami Murakami4,5, Akitada Ichinose2,3, Hiroshi Handa1.
Abstract
Autoimmune factor V deficiency (AiF5D) is caused by autoantibodies to coagulation factor V (FV); its clinical manifestations range from asymptomatic to fatal hemorrhage. Herein, we report the case of a 68-year-old man who was diagnosed with end-stage renal disease at the time of a femoral fracture and developed AiF5D after initiating hemodialysis. A wound infection that occurred after joint replacement was treated with antibiotics; however, it was poorly controlled. One month after the procedure, his coagulation time prolonged. The infection was improved by debridement and antibiotics; however, the coagulation time was not decreased and poor hemostasis at the shunt was still persistent. Because ELISA detected anti-FV-binding IgG with FV activity of <2.8% and FV inhibitor levels were 11.8 BU/ml, AiF5D was diagnosed. Oral prednisolone (PSL) was started. Dialysis was initially performed without anticoagulants, but blood clots were not found in the circuit. Anticoagulants were resumed when the coagulation time decreased. After achieving complete remission, PSL dose was tapered and finally discontinued. Few reports have described the management of AiF5D via dialysis. We consider that our report would be useful for the management of patients with similar manifestations.Entities:
Keywords: Acquired factor V inhibitor; Autoimmune factor V deficiency; Coagulation factor V; Hemodialysis
Year: 2020 PMID: 32507806 DOI: 10.11406/rinketsu.61.445
Source DB: PubMed Journal: Rinsho Ketsueki ISSN: 0485-1439